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ABSTRACT
Cetuximab is an effective drug used to treat patients 
with recurrent or metastatic head and neck squamous 
cell carcinoma. Skin toxicities such as paronychia and 
skin exsiccation are common adverse events caused by 
cetuximab. Skin toxicities may cause significant physi-
cal and psychosocial discomfort. The goal of managing 
skin toxicities is to minimize the detrimental effects 
on quality of life and continue the treatment. In one 
patient, skin toxicities became severe, up to grade 2, 
during treatment. The pain induced by paronychia and 
skin exsiccation made daily life difficult. Ten days after 
starting Unseiin, symptoms and finger findings resolved 
significantly. The patient could resume daily activities. 
No adverse effects induced by Unseiin were observed 
during treatment. Unseiin was effective on paronychia 
and skin exsiccation in this case and may contribute 
to successful treatment of skin toxicities induced by 
cetuximab.
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Cetuximab (Cmab) is an effective drug for patients with 
recurrent or metastatic head and neck squamous cell 
carcinoma (HNSCC).1, 2 Skin toxicities such as paro-
nychia and skin exsiccation are adverse events that are 
more commonly associated with Cmab than anti-cancer 
agents such as platinum-based drugs, taxanes, and 
fluoropyrimidine-based formulations which have been 
used in patients with HNSCC.3–5 Skin toxicities are seen 
in approximately 80% of patients treated with Cmab.6–8 
However, paronychia and skin fissures often cause 
severe, intolerable pain in the fingers and toes, although 
they are rarely life-threatening.9–11 These adverse events 
make it impossible to perform daily life activities such 
as grasping something and walking. When these ad-
verse events are severe, quality of life (QOL) is impaired 
because of pain and discomfort.12 This leads to loss of 
motivation and treatment compliance. Unless properly 
managed, they can result in dose reduction and discon-
tinuation of treatment, which occurs in approximately 
15–25% of patients.13, 14 Cmab should be continued if 
it has a confirmed therapeutic effect. It is reported that 
the management such as topical corticosteroids or oral 
tetracyclines have been used for the treatment of skin 
toxicities.15 However, definitive management for skin 
toxicities induced by Cmab has not been established yet. 
Therefore, effective management of these skin toxicities 
is required to maximize treatment efficacy and maintain 
QOL.
PATIENT REPORT
The patient was a 64-year-old man. He had previously 
received treatment for hypopharyngeal HNSCC (stage 
cT1N2bM0) consisting of cisplatin-based concomitant 
chemoradiotherapy and bilateral neck dissection. 
Lymph node metastasis was found in the left neck 37 
months after these treatments. Intravenous Cmab and 
carboplatin once weekly were planned as maintenance 
chemotherapy. The patient’s past medical history in-
cluded heart failure and coronary atherosclerosis.
Initial carboplatin dosage based on the Calvert 
method was only approximately 300 mg. The initial 
dosage of Cmab was 400 mg/m2. The Cmab dosage 
after initial administration was 250 mg/m2 once a week. 
His other medications included minocycline 100 mg/
day and a moisturizer to reduce the severity of skin 
toxicity at the same time as the start of initial dosage 
of Cmab (day 1). A grade 1 acneiform rash was found 
5 days after the initial Cmab dose. Cmab-induced skin 
toxicity was evaluated and graded using the Common 
Toxicity Criteria for Adverse Events version 4.0 by the 
same medical oncologist throughout treatment. Table 1 
shows that skin toxicity included rash acneiform, skin 
pain, and subcutaneous tissue disorders, that is, others, 
specifically paronychia and skin fissures.
Patient ReportYonago Acta Medica 2020;63(4):379–384 doi: 10.33160/yam.2020.11.020
Corresponding Author: Kenkichiro Taira, MD
kenkichiro.t@tottori-u.ac.jp
Received 2020 October 1
Accepted 2020 October 28
Online published 2020 November 24
Abbreviations: AD, atopic dermatitis; ADL, activities of daily 
livings; Cmab, cetuximab; EGFR, epidermal growth factor recep-
tor inhibitor; HNSCC, head and neck squamous cell carcinoma; 
QOL, quality of life
380
K. Taira et al.
© 2020 Tottori University Medical Press
A steroid was started for topical use to manage 
skin toxicity since acneiform rash was found (day 5). 
Paronychia and skin fissures caused by skin exsiccation 
on several fingers were found one day after the second 
Cmab dose (day 9). These skin toxicities became severe, 
up to grade 2, before the third Cmab dose (Fig. 1). 
Subsequently, finger pain progressed to grade 3, which 
made it difficult to hold chopsticks and pencils as part 
of daily life activities. In addition to the initial manage-
ment for skin toxicities, a Japanese traditional medicine 
(Kampo) called Unseiin was prescribed at 2.5 g three 
times daily when the third Cmab dose was started (day 
22). At 10 days after starting Unseiin, symptoms and 
findings in the fingers resolved significantly (Fig. 2). 
The patient could resume daily activities. Cmab was 
continued with no exacerbation of these skin toxici-
ties for the third to fifth doses. Two months later, CT 
showed progression of lymph node metastasis and 
chemotherapy was discontinued. No adverse effects as-
sociated with Unseiin were observed during treatment. 
The clinical course is shown in Fig. 3.
DISCUSSION
It has been reported that more than 80% of patients who 
receive Cmab experience skin toxicity; approximately 
25% of patients require treatment interruption or 
discontinuation.6–8, 13, 14 The skin toxicities induced by 
Cmab usually lessen within 1 month after discontinu-
ation.15, 16 However, occurrence of more severe Cmab-
induced skin toxicity is correlated with better treatment 
response and longer survival in several studies across 
multiple malignancies.12, 17, 18 Cmab therapy should be 
continued if it has a therapeutic effect. Therefore, it is 
important to manage skin toxicities such as paronychia 
and skin fissures because treatment interruption and 
discontinuation due to the severity of skin toxicity 
should be avoided in order to achieve maximum benefit. 
In our case, the paronychia and skin fissures had to be 
improved because of significant pain, functional limita-
tion, and impairment in daily living. Topical corticoste-
roid and anti-inflammatory dose tetracycline to decrease 
periungual inflammation and antimicrobial to prevent 
superinfection are recommended for paronychia.19–21 
Skin fissures and cracks often occur in the fingertips 
due to significant xerosis.15 Liquid glues like cyanoac-
rylate preparations can be used to seal the cracks and 
Table 1. Grading skin toxicities associated with EGFR inhibitors according to NCI-CTC AE version 4.0
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Rash acneiform Papules and/or 
pustules covering 
<10% BSA which 
may or may not 
be associated with 
symptoms of pruri-
tus or tenderness
Pa p u l e s a n d /o r 
pustules covering 
10 - 30 % B SA , 
which may or may 
not be associated 




impact; l imit ing 
instrumental ADL
Pa p u l e s a n d /o r 
pustules covering 
>30% BSA, which 
may or may not 
be associated with 
symptoms of pru-
ritus or tenderness; 
limiting self care 
ADL; associated 
with local super-




any % BSA, which 
may or may not 
be associated with 
symptoms of pru-
ritus or tenderness 
and are associ-













ous tissue disorders, 
and others specifi-





























BSA, body surface area.
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keep them from worsening.22–25 Hydrocortisone with 
moisturizer and prophylactic minocycline 100 mg daily 
is possible as an effective agent in improving acneiform 
rash.15 However, there have been no clear effectiveness 
patterns for these skin toxicities.12, 15, 26 In our case, 
these treatments were less effective. Thus, more effec-
tive agents had to be taken into consideration to reduce 
the discomfort of skin toxicities.
This is the first report showing that Unseiin is 
effective for skin toxicities induced by Cmab. In our 
patient, skin toxicity was progressing due to the con-
tinuation of Cmab. Unseiin was effective for paronychia 
and skin fissures; these symptoms of skin toxicities 
lessened without treatment interruption. Unseiin is used 
to treat pruritic cutaneous diseases such as eczema and 
skin eruptions.27 Four herbal compounds including 
Unseiin are effective for inflammatory skin disease 
such as atopic dermatitis (AD) that involve a skin bar-
rier defect.28 These four herbal compounds are Coptis 
Chinensis, Phellodendri Cortex, Scutellariae Radix, 
Gardeniae Fructus which can correct the Th1/Th2 cells 
balance skewed to Th2 cells.28
Cmab inhibits the expression of epidermal growth 
factor receptor (EGFR) in the skin.9 Inhibition of 
EGFR-mediated signaling pathways reduces kerati-
nocyte proliferation by inducing growth arrest and 
apoptosis, decreasing cell migration, and increasing 
cell attachment and differentiation.9, 29 These effects 
lead to defective barrier function of the skin. Chronic 
impairment of the skin barrier in conditions like AD 
leads to direct exposure to antigens and upregulation of 
Th2 activity, thereby increasing cytokine production.30 
Fig. 1. Before treatment with Unseiin. Paronychia and skin fissures caused by skin exsiccation. A: Right fingers. B: Left fingers.
Fig. 2. Ten days after treatment with Unseiin. Significant improvement of skin exsiccation. A: Right fingers. B: Left fingers.
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This causes further progression of the skin disorder. 
Unseiin including four herbal compounds suppresses 
hypersensitivity reactions associated with Th2 cells. It 
seems to downregulate Th2 activity and prevent severe 
dermatitis.
Skin barrier defects cause secondary bacte-
rial infections, which can worsen the symptoms of 
skin inf lammation. Unseiin is composed of eight 
herbal compounds: Coptis Chinensis, Phellodendri 
Cortex, Scutellariae Radix, Gardeniae Fructus, 
Angelicae Radix, Cnidii Rhizoma, Paeoniae Radix, 
and Rehmanniae Radix. Several herbal substances are 
associated with mechanisms that reduce the severity of 
inflammation and pain. It has been reported that Coptis 
Chinensis and Angelicae Radix have antibacterial ac-
tivities31 and Coptis Chinensis and Phellodendri Cortex 
have anti-inflammatory activity and suppress the pro-
duction of prostaglandin E2, which induces pain.32–37 
We speculate that these pharmacological actions are 
effective for reducing symptoms and the severity of skin 
toxicities caused by Cmab. In this case, chemotherapy 
was completed because of reduced skin toxicity after 
Unseiin was started. Therefore, Unseiin may contribute 
to successful treatment of skin toxicities induced by 
Cmab. One limitation is shown in a case report of a 
patient with head and neck cancer where there is a lack 
of evidence-based clinical guidelines for management. 
More data are needed to confirm the positive relation-
ship between skin toxicity and clinical response of 
Unseiin.
In conclusion, Unseiin was effective for paronychia 
and skin exsiccation. Further studies are also required 
to fully understand the biological activity of Unseiin 
against skin toxicities.
Consent for publication: Informed consent was obtained from 
the patient regarding the publication of the details of this case 
and associated images.
The authors declare no conflict of interest.
Fig. 3. Clinical course. Cmab could be continued without interruption.
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